These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3181250)

  • 1. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients.
    Robert J; David M; Huet S; Chauvergne J
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1289-94. PubMed ID: 3181250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
    Robert J; Monnier A; Poutignat N; Hérait P
    Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of pirarubicin in pediatric patients.
    Nagasawa K; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K; Kosaka Y; Sano K; Murakami R; Nakamura H
    J Pharmacobiodyn; 1991 Apr; 14(4):222-30. PubMed ID: 1941503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
    J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.
    Bugat R; Robert J; Herrera A; Pinel MC; Huet S; Chevreau C; Boussin G; Roquain J; Carton M
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):505-11. PubMed ID: 2703005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of pirarubicin in human blood.
    Nagasawa K; Kitada N; Tsuji C; Ogawa M; Yokoyama T; Ohnishi N; Iwakawa S; Okumura K
    Chem Pharm Bull (Tokyo); 1992 Oct; 40(10):2866-9. PubMed ID: 1464120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
    Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
    Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of doxorubicin and its metabolite doxorubicinol in rabbits with induced acid and alkaline urine.
    Johansen PB; Jensen SE; Rasmussen SN; Dalmark M
    Cancer Chemother Pharmacol; 1984; 13(1):5-8. PubMed ID: 6329539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
    Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
    Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
    Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
    Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
    Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
    Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
    Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
    J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.
    Baldwin JR; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Cancer Chemother Pharmacol; 1992; 30(6):433-8. PubMed ID: 1394799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
    Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.
    Brenner DE; Galloway S; Cooper J; Noone R; Hande KR
    Cancer Chemother Pharmacol; 1985; 14(2):139-45. PubMed ID: 3971478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Iliadis A
    Cancer Chemother Pharmacol; 1995; 36(3):233-8. PubMed ID: 7781144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans.
    Mross K; Mayer U; Hamm K; Burk K; Hossfeld DK
    Eur J Clin Pharmacol; 1990; 39(5):507-13. PubMed ID: 2076745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.